SC
EPRX

Steven Cohen’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Steven Cohen’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.83M Sell
730,284
-237,291
-25% -$1.64M 0.01% 1787
2026
Q1 		$7.01M Buy
967,575
+255,471
+36% +$2.06M 0.01% 1472
2025
Q4 		$5.38M Buy
+712,104
New +$4.39M 0.01% 1791

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Steven Cohen's EPRX Position: Q2 2026 in Review

Steven Cohen reduced its Eupraxia Pharmaceuticals (EPRX) stake by 25% in Q2 2026, selling an estimated $1.64M and leaving 730,284 shares worth $4.83M. The position accounts for 0.01% of the portfolio, ranked #1787.

Steven Cohen first reported a position in EPRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.01M in Q1 2026. 68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Steven Cohen held 730,284 shares of Eupraxia Pharmaceuticals worth $4.83M as of Q2 2026.
  • Steven Cohen sold 237,291 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $1.64M.
  • Eupraxia Pharmaceuticals made up 0.01% of Steven Cohen's portfolio in Q2 2026, its #1787 holding.
  • Steven Cohen first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Steven Cohen's Eupraxia Pharmaceuticals position peaked at $7.01M in Q1 2026.
  • 68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.